甲状腺癌与外周静脉血炎性相关指标

doi:10.6040/j.issn.1673-3770.1.2017.048

山东大学耳鼻喉眼学报 ›› 2017, Vol. 31 ›› Issue (6): 21-24.doi: 10.6040/j.issn.1673-3770.1.2017.048

• 甲状腺癌的规范化诊断与治疗·专题笔谈 • 上一篇下一篇

甲状腺癌与外周静脉血炎性相关指标

普布次仁¹,刘吉峰²,巴罗³

1.西藏自治区人民医院普外科, 西藏拉萨 850000;
2.四川省肿瘤医院头颈外科, 四川成都 610047;
3.西藏自治区人民医院耳鼻咽喉科, 西藏拉萨 850000

收稿日期:2017-11-06 出版日期:2017-12-16 发布日期:2017-12-16
通讯作者: 巴罗. E-mail:bhanor@163.com
基金资助:
西藏自治区科技厅自然基金(Z2012A60G32/00);四川省医学会资助课题(S15077)

Relationship between thyroid cancer and hematological components of the systemic inflammatory response.

PUBU Ciren¹, LIU Jifeng², BA Luo³

1. Department of General Surgery, Peoples Hospital of Tibet Autonomous Region, Lhasa 850000, Tibet, China;2. Department of Head and Neck Surgery, Sichuan Cancer Hospital, Chengdu 610047, Sichuan, China;3. Department of Otolaryngology, Peoples Hospital of Tibet Autonomous Region, Lhasa 850000, Tibet, China

Received:2017-11-06 Online:2017-12-16 Published:2017-12-16

摘要/Abstract

摘要： 包括甲状腺癌在内的多种恶性肿瘤,证据表明其预后与反应系统的炎症反应的血液学指标相关。越来越多地研究关注甲状腺癌和中性-淋巴细胞比、血小板-淋巴细胞计数比值、C反应蛋白的关系。就这些血液学相关指标与甲状腺癌的研究进展做一综述。

关键词: 甲状腺癌, 血小板-淋巴细胞比, 中性-淋巴细胞比

Abstract: In a variety of cancers, including thyroid cancer, hematological components of the systemic in ammatory response have been shown to have prognostic value.Most previous studies have focused on the relationship between thyroid cancer and hematological components, such as neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and C-reactive protein.This paper aimed to report the advance of the association between these hematological data and thyroid cancer.

Key words: Neutrophil-to-lymphocyte ratio, Platelet-to-lymphocyte count ratio, Thyroid cancer

中图分类号:

R736.1

普布次仁,刘吉峰,巴罗. 甲状腺癌与外周静脉血炎性相关指标[J]. 山东大学耳鼻喉眼学报, 2017, 31(6): 21-24.

PUBU Ciren, LIU Jifeng, BA Luo. Relationship between thyroid cancer and hematological components of the systemic inflammatory response.[J]. J Otolaryngol Ophthalmol Shandong Univ, 2017, 31(6): 21-24.

参考文献

[1] Zhou GJ, Xiao M, Zhao LN, et al. MicroRNAs as novel biomarkers for the differentiation of malignant versus benign thyroid lesions: a meta-analysis[J]. Genet Mol Res, 2015, 14(3):7279-7289.
[2] 王宇,马奔. 超声引导下热消融技术尚不适用于甲状腺癌及甲状腺滤泡性肿瘤治疗[J]. 山东大学耳鼻喉眼学报,2016, 30(2):20-22. WANG Yu, MA Ben. Ultrasound guided thermoablation does not fit for thyroid carcinoma and follicular neoplasm[J]. J Otolaryngol Ophthal Shandong Univ,2016, 30(2):20-22.
[3] Jiang K, Lei J, Chen W, et al. Association of the preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios with lymph node metastasis and recurrence in patients with medullary thyroid carcinoma[J]. Medicine(Baltimore), 2016, 95(40):5079.
[4] Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape[J]. Cytokine Growth Factor Rev, 2007, 18(1-2):171-182.
[5] Dalpiaz O, Pichler M, Mannweiler S, et al. Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma[J]. Br J Cancer, 2014, 110(10):2531-2536.
[6] Liu CL, Lee JJ, Liu TP, et al. Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer[J]. J Surg Oncol, 2013, 107(5):493-497.
[7] Wenger FA, Jacobi CA, Zieren J, et al. Tumor size and lymph-node status in pancreatic carcinoma- is there a correlation to the preoperative immune function?[J]. Lang Arch Surg, 1999, 384(5):473-478.
[8] Guarino V, Castellone MD, Avilla E, et al. Thyroid cancer and inflammation[J]. Mol Cell Endocrinol, 2010, 321(1):94-102.
[9] Larson SD, Jackson LN, Riall TS, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway[J]. J Am Coll Surg, 2007, 204(5):764-773.
[10] Bradly DP, Reddy V, Prinz RA, et al. Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases[J]. Surgery, 2009, 146(6):1099-1104.
[11] Proctor MJ, McMillan DC, Morrison DS, et al. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer[J]. Br J Cancer, 2012, 107(4):695-699.
[12] Clarke SJ, Chua W, Moore M, et al. Use of inflammatory markers to guide cancer treatment[J]. Clin Pharmacol Ther, 2011, 90(3):475-478.
[13] Seretis C, Gourgiotis S, Gemenetzis G, et al. The significance of neutrophil/lymphocyte ratio as a possible marker of underlying papillary microcarcinomas in thyroidal goiters: a pilot study[J]. Am J Surg, 2013, 205(6):691-696.
[14] Kim JY, Park T, Jeong SH, et al. Prognostic importance of baseline neutrophil to lymphocyte ratio in patients with advanced papillary thyroid carcinomas[J]. Endocrine, 2014, 46(3): 526-531.
[15] Kocer D, Karakukcu C, Karaman H, et al. May the neutrophil/lymphocyte ratio be a predictor in the differentiation of different thyroid disorders?[J]. Asian Pac J Cancer Prev, 2015, 16(9):3875-3879.
[16] Liu J, Du J, Fan J, et al. The Neutrophil-to-lymphocyte ratio correlates with age in patients with papillary thyroid carcinoma[J]. ORL J Otorhinolaryngol Relat Spec, 2015, 77(2):109-116.
[17] Kim SM, Kim EH, Kim BH, et al. Association of the preoperative neutrophil-to-ymphocyte count ratio and platelet-to-lymphocyte count ratio with clinicopathological characteristics in patients with papillary thyroid cancer[J]. Endoc Metab(Seoul), 2015, 30(4): 494-501.
[18] Liu JF, Ba L, Lv H, et al. Association between neutrophil-to-lymphocyte ratio and differentiated thyroid cancer: a meta-analysis[J]. Sci Rep, 2016, 6:38551.
[19] Cho JS, Park MH, Ryu YJ, et al. The neutrophil to lymphocyte ratio can discriminate anaplastic thyroid cancer against poorly or well differentiated cancer[J]. Ann Surg Treat Res, 2015, 88(4):187-192.
[20] Gu XB, Tian T, Tian XJ, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis[J]. Sci Rep, 2015, 5:12493.
[21] Lang BH, Ng CP, Au KB, et al. Does preoperative neutrophil lymphocyte ratio predict risk of recurrence and occult central nodal metastasis in papillary thyroid carcinoma?[J]. World J Surg, 2014, 38(10):2605-2612.
[22] Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer[J]. Future Oncol, 2010, 6(1):149-163.
[23] Yaylaci S, Tosun O, Sahin O, et al. Lack of variation in inflammatory hematological parameters between benign nodular goiter and papillary thyroid cancer[J]. Asian Pac J Cancer Prev, 2016, 17(4):2321-2323.
[24] Sun C, Li Q, Hu Z, et al. Treatment and prognosis of anaplastic thyroid carcinoma: experience from a single institution in China[J]. PLoS One, 2013, 8(11):e80011.
[25] Ahmed SR, Ball DW. Clinical review: Incidentally discovered medullary thyroid cancer: diagnostic strategies and treatment[J]. J Clin Endocrinol Metab, 2011, 96(5):1237-1245.
[26] Guo YZ, Pan L, Du CJ, et al. Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies[J]. Asian Pac J Cancer Pre, 2013, 14(1):243-248.
[27] Hou X, Jiang L, Chen C, et al. Different expression of erythrocyte sedimentation rate and c-reactive protein in papillary thyroid carcinoma and nodular goiter[J]. Clin Lab, 2015, 61(7):793-799.
[28] Stanciu AE, Serdarevic N, Hurduc AE, et al. IL-4,IL-10 and high sensitivity-CRP as potential serum biomarkers of persistent/recurrent disease in papillary thyroid carcinoma with/without Hashimotos thyroiditis[J]. Scand J Clin Lab Invest, 2015, 75(7):539-548.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed

甲状腺癌与外周静脉血炎性相关指标

Relationship between thyroid cancer and hematological components of the systemic inflammatory response.

HTML

PDF (PC)

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 12

多维度评价

本文评价

推荐阅读 0

[1]	孙国臣,孙彦,张虹,王保为. 儿童分化型甲状腺癌的临床特征及治疗体会[J]. 山东大学耳鼻喉眼学报, 2017, 31(6): 25-28.
[2]	潘永杰,庞文会,孙国臣,孙彦,张虹. 乙酰肝素酶和D2-40在儿童甲状腺癌中的表达及临床意义[J]. 山东大学耳鼻喉眼学报, 2017, 31(6): 29-32.
[3]	邱杰,孙莎莎,孙彦. 美国癌症联合委员会第8版甲状腺癌TNM分期解读[J]. 山东大学耳鼻喉眼学报, 2017, 31(6): 5-8.
[4]	徐书杭, 李春睿, 刘超. 儿童甲状腺癌的规范化诊治[J]. 山东大学耳鼻喉眼学报, 2017, 31(6): 12-15.
[5]	余济春. 分化型甲状腺癌颈淋巴结清扫术[J]. 山东大学耳鼻喉眼学报, 2016, 30(2): 10-12.
[6]	邱杰,孙彦. 肿瘤标志物检测在甲状腺癌临床诊治中的意义[J]. 山东大学耳鼻喉眼学报, 2016, 30(2): 28-31.
[7]	李莹莹综述, 宋西成审校. DNA双链断裂修复基因的单核苷酸多态性与甲状腺癌的研究进展[J]. 山东大学耳鼻喉眼学报, 2016, 30(2): 102-105.
[8]	赵国伟，贺青卿，庄大勇，郑鲁明，范子义，朱见，于芳，周鹏，侯蕾，姜会平. ¹³¹I治疗分化型甲状腺癌的应用价值与风险[J]. 山东大学耳鼻喉眼学报, 2013, 27(6): 16-21.
[9]	曹磊，贺青卿，庄大勇，郑鲁明，范子义，周鹏，朱见. 选择低位小切口行甲状腺癌选择性淋巴结清扫[J]. 山东大学耳鼻喉眼学报, 2013, 27(2): 56-59.
[10]	范林军1,明佳1,黄定德2，范子义1, 赵德龙3,张毅1,杨新华1,姜军1. 腔镜甲状腺近全切除序贯131I消融治疗分化型甲状腺癌[J]. 山东大学耳鼻喉眼学报, 2011, 25(5): 11-16.
[11]	伊海金1，张宝泉2. 甲状腺癌的外科治疗分析[J]. 山东大学耳鼻喉眼学报, 2010, 24(4): 10-12.
[12]	张虎,艾琴 . 甲状腺癌再手术15例[J]. 山东大学耳鼻喉眼学报, 2007, 21(2): 166-167 .